chemotherapy-induced neuropathy: standard and innovative ... · standard and innovative treatment...
TRANSCRIPT
![Page 1: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/1.jpg)
Chemotherapy-Induced Neuropathy: Standard and Innovative Treatment
Approaches
Charles Loprinzi MD Regis Professor of Breast Cancer Research
![Page 2: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/2.jpg)
Potential Conflicts of Interest
• Competitive Technologies provided a machine and supplies for research
• Pfizer provided funding for a study
• I have spoken to many interested companies
• Virtually all of which I discuss will not be FDA approved
![Page 3: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/3.jpg)
![Page 4: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/4.jpg)
• 1,225 potentially relevant citations
• 250 examined in detail
• 48 eligible for guideline evidentiary basis
• 42 for CIPN prevention
• 6 for CIPN treatment
![Page 5: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/5.jpg)
Treatment agents reviewed
• Duloxetine • Gabapentin • Topical BAK • Tricyclic antidepressants • Acetyl-L-carnitine • Lamotrigine
![Page 6: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/6.jpg)
Treatment agents recommended against
• Duloxetine • Gabapentin • Topical BAK • Tricyclic antidepressants • Acetyl-L-carnitine • Lamotrigine
![Page 7: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/7.jpg)
Treatment agent recommended
• Duloxetine • Gabapentin • Topical BAK • Tricyclic antidepressants • Acetyl-L-carnitine • Lamotrigine
![Page 8: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/8.jpg)
A PHASE III DOUBLE BLIND TRIAL OF ORAL DULOXETINE FOR TREATMENT OF PAIN
ASSOCIATED WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN)
Ellen Smith, Tim Ahles, Ethan Basch et al
JAMA. Smith et al JAMA; 2013;309:1359-67
![Page 9: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/9.jpg)
R
CP1347589-9
JAMA. Smith et al JAMA; 2013;309:1359-67
Chemotherapy-induced neuropathy
Duloxetine 30 mg/d for 1 week 60 mg/d for 4 weeks
Placebo 1/d for 1 week 2/d for 4 weeks
![Page 10: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/10.jpg)
Date of download: 4/3/2014 Copyright © 2014 American Medical
Association. All rights reserved.
From: Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced
Painful Peripheral Neuropathy: A Randomized Clinical Trial
JAMA. 2013;309(13):1359-1367. doi:10.1001/jama.2013.2813
![Page 11: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/11.jpg)
Date of download: 4/3/2014 Copyright © 2014 American Medical
Association. All rights reserved.
From: Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced
Painful Peripheral Neuropathy: A Randomized Clinical Trial
JAMA. 2013;309(13):1359-1367. doi:10.1001/jama.2013.2813
![Page 12: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/12.jpg)
2014 ASCO/MASCC Palliative Care: Yasuo Hirayama et al J Clin Oncol 32,
2014 (suppl 31; abstr 181)
• Japanese pts randomized to receive duloxetine followed by vitamin B12 versus vitamin B12 followed by duloxetine
• 34 cases
• 5 cases dropped out because of adverse effects
• Significant differences in changes of VAS were observed
between duloxetine group and VB12 group for:
• numbness (p=0.02) • pain (p=0.03)
![Page 13: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/13.jpg)
Duloxetine in symptomatic chemotherapy-induced peripheral
neuropathy: Single-center experience beyond the clinical trial
Roser Velasco et al University Hospital of Bellvitge, Barcelona,
Spain; ASCO 2015; Abstract e20713
![Page 14: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/14.jpg)
• Single-institution consecutive cancer patients with CIPN
• Treated with duloxetine in 2014 • Prospectively collected data
![Page 15: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/15.jpg)
Study aim was to evaluate: • Drug efficacy
• Rate of compliance
• Adverse-effects profile
![Page 16: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/16.jpg)
• 73 pts treated: • 45 (62%) patients discontinued duloxetine related
to: • Side-effects (38%) • Ineffectiveness (23%)
Drug dosing details not provided.
![Page 17: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/17.jpg)
Conclusions Regarding Duloxetine
• It does work • Benefit is limited • Toxicity is a problem for some
![Page 18: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/18.jpg)
Treatment agents endorsed
• Duloxetine • Gabapentin • Topical BAK • Tricyclic antidepressants • Acetyl-L-carnitine • Lamotrigine
![Page 19: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/19.jpg)
Have you been using gabapentinoids for treatment of established neuropathy?
What percentage of patients get mild or more
benefit?
What percentage of patients get marked
benefit?
N -- -- N -- -- N -- -- N -- -- N -- -- N 10% 0
N 5-10% 0
Rarely -- -- Rarely -- -- Rarely 5% 0%
Occasionally 10-20% 0%
Occasionally -- --
Occasionally 20% 5%
Occasionally 10-20% <10%
Occasionally 20% 10%
Y 20% 0%
Y 10-40% <10%
Y 30-50% 10-20%
Y 45% >50%
Responses to questions re use of gabapentin Medical Oncologists
![Page 20: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/20.jpg)
Responses to questions re use of gabapentin Hematologists
Have you been using gabapentinoids for
treatment of established neuropathy?
What percentage of patients get mild or more
benefit?
What percentage of patients get
marked benefit?
Rarely -- -- Y 25% 5%
Y 20% 10%
Y 40-50% 10-20%
Y 25% 20%
Y 20% 30-40%
Y 50% 50%
![Page 21: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/21.jpg)
The first known report regarding the use of gabapentin for chemotherapy-induced
neuropathy:
Oxaliplatin-induced Neuropathy: Could Gabapentin be the Answer?
• Mariani et al • 2000 ASCO annual meeting
![Page 22: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/22.jpg)
• Gabapentin used in 7 patients receiving oxaliplatin who developed neuropathy
• With the initiation of neuropathy, gabapentin
was given at a dose of 100 mg twice per day • Increased to 100 mg three times daily if
symptoms did not resolve with the lower daily dose
• Disappearance of neuropathy symptoms
that continued even with the use of up to 14 total oxaliplatin doses
• Not available in manuscript form
![Page 23: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/23.jpg)
• 2006 report on two sequential cohorts of patients who received similar oxaliplatin treatments for metastatic colorectal cancer
• The second cohort also received gabapentin, 300 mg
daily initially….allowed to be increased to 600 mg three times daily
• Similar degrees of neurotoxicity were seen on both
arms
• No differences in the relative dose intensities of oxaliplatin
Mitchell PL, et al: Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clinical colorectal cancer 6:146-51, 2006
![Page 24: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/24.jpg)
• 2009, Czech Republic manuscript
• Pregabalin use in 30 children (mean age of 13.5 years) in an open label trial design2
9 • Variety of neurotoxic chemotherapy drugs and had a
pain score of at least 4/10 when entered on trial • Mean VAS decreased by 59%
• 86% of the evaluable patients had long-lasting pain
relief
Vondracek P et al: EJPN : official journal of the European Paediatric Neurology Society 13:332-6, 2009
![Page 25: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/25.jpg)
• In 2010, a report of 23 patients treated with pregabalin for oxaliplatin-induced neuropathy
• Appears to be a clinical practice experience, as opposed to a prospective clinical trial
• Authors felt that 40% of the patients responded to therapy, as judged by a neuropathy improvement of 1-2 grades
• Quite a few toxicities
Saif MW, et al: Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Research 30:2927-33, 2010
![Page 26: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/26.jpg)
• 2012 - 2014, 5 Japanese manuscripts related to pregabalin therapy for CIPN,with English abstracts • 2 single case reports-positive • 13 cases, ?clinical experience?, with 8
‘responding’ pts (62%) • 27 oxaliplatin CIPN prospective trial, it seems
• 27% ‘responded’ • 55 pts ?clinical experience?
• 28 pacltaxel-29% ‘responded’ • 27 oxaliplatin—41% ‘responded’
![Page 27: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/27.jpg)
Efficacy of Gabapentin in the Management of Chemotherapy-
Induced Peripheral Neuropathy: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Crossover Trial
(N00C3)
Rao R, Michalak J, Sloan J, Loprinzi C, Soori G, Nikcevich D, Warner D, Novotny P, Kutteh L, Wong G
CP1347589-27
Cancer 110; 2110: 2007
![Page 28: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/28.jpg)
R
CP1347589-28 Cancer 110, 2110; 2007
Chemotherapy-induced neuropathy
6 wk Gabapentin 2700 mg/day Placebo
Washout 2 wk
6 wk Placebo Gabapentin 2700 mg/day
![Page 29: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/29.jpg)
0
2
4
6
8
10
0 2 4 6 8 10 12 14
Placebo
Gabapentin
P=0.21 P=0.37
First period Wash-
out Second period
Mean Pain Intensity
CP1347589-29
Placebo
Gabapentin
Cancer 110, 2110; 2007
Mean Pain
Intensity
Time (weeks)
![Page 30: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/30.jpg)
More Data A Reported Randomized, Double-blind, Placebo-controlled Trial
• Pregabalin for the prevention/treatment of
CIPN • Conducted in patients with advanced
colorectal cancer receiving oxaliplatin-based chemotherapy
![Page 31: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/31.jpg)
More Data • Enrolled 64 patients • Primary endpoint of this trial was the duration-
adjusted average paresthesia change measured by a numerical rating scale
• Patients received flexible pregabalin dosing,
from 150-600 mg/day versus placebos
![Page 32: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/32.jpg)
More Data • The trial was terminated early • Interim analysis found that there was not
sufficiently positive data to continue the trial, based on a ‘conditional power to detect a difference in treatment groups’
ClinicalTrials.gov. prevention and treatment of chemotherapy-induced peripheral neuropathy in subjects with advanced colorectal cancer. https://Clinicaltrials.gov/ct2/show/NCT00380874 (accessed 4014 dec 25)
![Page 33: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/33.jpg)
Can Pregabalin Prevent Paclitaxel-Associated Neuropathy?—A Pilot Trial
S. S. Shinde, D. Seisler, G. Soori, P. J. Atherton, D. R. Pachman, J. Lafky, K. J. Ruddy, C L. Loprinzi
Ma
J Support Care in Cancer; on line ahead of publication
![Page 34: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/34.jpg)
![Page 35: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/35.jpg)
![Page 36: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/36.jpg)
![Page 37: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/37.jpg)
Treatment agents endorsed
• Duloxetine • Gabapentin • Topical BAK • Tricyclic antidepressants • Acetyl-L-carnitine • Lamotrigine
![Page 38: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/38.jpg)
Treatment agents endorsed
• Duloxetine • Gabapentin • Topical BAK • Tricyclic antidepressants • Acetyl-L-carnitine • Lamotrigine
![Page 39: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/39.jpg)
Scrambler Therapy: A Potentially Effective Treatment
Approach for CIPN
![Page 40: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/40.jpg)
Scrambler Therapy • Patient-specific cutaneous electro-stimulation
similar to spinal cord stimulation, but non-invasive
• Creates "non pain" information in packets of rapidly varying impulses, given non-invasively using the patients own nerves
• US FDA sanctioned Feb 09
![Page 41: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/41.jpg)
How did I get involved? • Initial disbelief • Promising pilot data • We obtained a machine to test this
product, in an investigative manner • > 200 patients
![Page 42: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/42.jpg)
Scrambler Therapy Results
• 15 trials/reports available • 12 published manuscripts • 2 published abstracts • 1 Mayo study not yet published
![Page 43: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/43.jpg)
Scrambler Therapy Results
• 4 clinical practice experiences • 8 prospective-IRB approved • 1 randomized controlled trial • 2 randomized pt-blinded PC trials
![Page 44: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/44.jpg)
How does Scrambler therapy work?
![Page 45: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/45.jpg)
![Page 46: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/46.jpg)
First Trial
• 11 cancer patients with drug resistant visceral pain
• 3 pancreas
• 4 colon
• 4 gastric
Marineo G: Untreatable pain resulting from abdominal cancer: new hope
from biophysics? Jop 4:1-10, 2003
![Page 47: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/47.jpg)
• Pain was quickly and markedly reduced
• 9 of 11 stopped pain drugs in the first 5 applications
• No side effects
• Pain reductions continued until death
• Recurrent pain, months later, successfully retreated.
First Trial
Marineo G: Untreatable pain resulting from abdominal cancer: new hope
from biophysics? Jop 4:1-10, 2003
![Page 48: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/48.jpg)
First Trial
Marineo G: Untreatable pain resulting from abdominal cancer: new hope
from biophysics? Jop 4:1-10, 2003
![Page 49: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/49.jpg)
Second Trial • 226 patients with neuropathic pain
• Prospective study, details sketchy • Failed back surgery, brachial plexus neuropathy, and
others • 80% of patients responded with > 50% pain relief, • 10% responded with pain relief from 25% to 49% • 10% had no response.
• No toxicities were noted
Sabato, Marineo G, Gatti A: Calmare therapy. Minerva Anestesiol 71:479-82, 2005
![Page 50: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/50.jpg)
Pilot trial of a Patient-specific Cutaneous Electro-stimulation Device (MC5-A Calmare®)
for Chemotherapy Induced Peripheral Neuropathy
Thomas J. Smith MD, Patrick J. Coyne RN MSN, Patricia Dodson BSN MA, , Gwendolyn Parker RN MSN, V.
Ramakrishnan, PhD
Massey Cancer Center of Virginia Commonwealth University
Smith et al, J Pain Symptom Manage 40:883-91, 2010
![Page 51: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/51.jpg)
0
1
2
3
4
5
6
7
1 2 3 4 5 6 7 8 9 10
Days of therapy
CIP
N P
ain
Scor
e 0-
10
CIPN Mean
Unadjusted CIPN "pain now" scores
Third Trial
Smith et al, J Pain Symptom Manage 40:883-91, 2010
![Page 52: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/52.jpg)
Marineo G et al, J Pain Symptom Manage. 2012 43(1):87-95
• 52 patients with chronic neuropathic pain • Randomized to Scrambler vs standard
pharmacology guidelines • Post surgical, post herpetic, or spinal
cord stenosis • Mean pain scores of 8.1, despite medical
therapy
Fifth Trial
![Page 53: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/53.jpg)
Control
Scrambler
Fifth Trial
Marineo G et al, J Pain Symptom Manage. 2012 43(1):87-95
![Page 54: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/54.jpg)
• DB, PC, R trial
• 14 pts with CIPN
• Little experience
• No differences between arms; no placebo effect
• Sham procedure looked viable
• ASCO abstract; no manuscript
Campbell, et al; J Clin Oncol 31, 2013 (suppl; abstr 9635)
Eleventh Trial/Report
![Page 55: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/55.jpg)
Scrambler Therapy for the Treatment of Neuropathy and Pain: An Open Access Trial
Twelfth Trial/Report
![Page 56: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/56.jpg)
Eligibility • Pts had pain or CIPN symptoms of ≥1 month
duration with tingling and/or pain ≥4/10 during the prior week
Treatment • Patients were treated with Scrambler therapy
to the affected area(s) for up to 10 daily 30 minute sessions
![Page 57: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/57.jpg)
Initial CIPN Patient Cohort
Pachman et al; Sup Care in Cancer, 2014
![Page 58: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/58.jpg)
Patients • First 37 patients enrolled on study
• 25 were treated primarily on their lower extremities
• 12 were treated primarily on their upper
extremities.
Pachman et al; Sup Care in Cancer, 2014
![Page 59: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/59.jpg)
Current Pain
0
1
2
3
4
5
6
7
8
9
10
1 2 3 4 5 6 7 8 9 10
Pain
sco
res
No. of pt 37 36 36 34 28 24 23 22 20 20
Days
Pre-therapy Post-therapy
Pachman et al; Sup Care in Cancer, 2014
![Page 60: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/60.jpg)
Effect of Scrambler Therapy on Average CIPN Scores
Symptom
Mean baseline
score
Mean final
score
Average drop in symptom score (%) P
Pain 5.7 2.6 53 <0.0001 Tingling 6.0 3.3 44 0.0001 Numbness 6.3 4.0 37 0.0002
Pachman et al; Sup Care in Cancer, 2014
![Page 61: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/61.jpg)
0
1
2
3
4
5
6
7
8
9
10
1 2 3 4 5 6 7 8 9 10
Mean Symptom Severity in the Past 24 Hours
Days
Sym
ptom
sco
res
(mea
n)
Tingling
No. of pt 37 36 36 34 28 24 23 22 20 20
Numbness
Pain
Pachman et al; Sup Care in Cancer, 2014
![Page 62: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/62.jpg)
0
1
2
3
4
5
6
7
8
9
10
1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10
Mean Symptom Severity
Days
Sym
ptom
sco
res
(mea
n)
Tingling
Patient numbers
Numbness Pain
Week
14 12 13 13 13 12 12 12 12 12 37 36 36 34 28 21 23 22 20 20 14 13 13 13 13 12 12 12 12 12 37 36 36 34 28 24 23 22 20 20 14 13 13 13 13 12 12 12 12 12 37 36 36 34 28 24 23 22 20 20
26 23 23 23 23 23 22 22 22 22 37 36 36 34 28 24 23 22 20 20
Numbness, tingling or pain
Pachman et al; Sup Care in Cancer, 2014
![Page 63: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/63.jpg)
0
1
2
3
4
5
6
7
8
9
10
1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10
Average Numbness, Tingling, or Pain
Days
Sym
ptom
sco
res
(mea
n)
Numbness, tingling, or pain (earlier cohort)
No. of pt
Numbness, tingling, or pain (later cohort)
Week 14 13 13 13 13 12 12 12 12 12 14 14 14 14 14 14 14 13 13 13 12 10 10 10 10 10 10 10 10 9 23 22 22 20 14 10 9 8 7 7
Numbness, tingling or pain
Pachman et al; Sup Care in Cancer, 2014
![Page 64: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/64.jpg)
0
1
2
3
4
5
6
7
8
9
10
1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10
Average Numbness, Tingling, or Pain by Date Registered
Days
Sym
ptom
sco
res
(mea
n)
Last 10
Patient numbers
First 9
Second 9
Week
6 4 4 4 4 4 4 4 4 3 9 8 8 8 5 3 3 2 2 2 6 5 5 5 5 5 5 5 5 5 9 9 9 9 9 7 7 7 5 5 8 8 8 8 8 7 7 7 7 7 10 10 10 10 9 9 9 9 9 9
6 6 6 6 6 6 6 6 6 6 9 9 9 7 5 5 4 4 4 4
Third 9
![Page 65: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/65.jpg)
Treatment Day 1 2 3 4 5 6 7 8 9 10
Study ID Change (%) Lower Extremity
1 5 7 2 2 0 0 0 0 0 0 -100% 2 4 4 6 2 1 0 0+ 0+ 0+ 0+ -100% 3 9 8 7 0 0+ 0+ 0+ 0+ 0+ 0+ -100% 4 5 4 3 0 0 1 0 0 0 0 -100% 5 8 8 0 3 3 2 1 1 0 0 -100% 6 5 5 5 5 4 3 3 2 0 0 -100% 7 5 5 5 4 3 3 2 2 1 0 -100% 8 6 4 2 2 2 3 2 1 1 1 -83.3% 9 6 5 4 4 3 5 3 2 2 1 -83.3%
10 8 7 7 5 5 5 4 3 2 2 -75.0% 11 5 5 7 5 6 5 2 2 4 2 -60.0% 12 6 6 5 5 5 4 4 4 4 3 -50.0% 13 5 5 5 5 5 5 3 3 4 3 -40.0% 14 8 8 7 6 6 6 6 5 5 5 -37.5% 15 8 5 6 6 5 6 5 5 5 5 -37.5% 16 8 8 7 5 5+ 5+ 5+ 5+ 5+ 5+ -37.5% 17 8 7 7 6 6 6 6 5 5 5 -37.5% 18 3 3 3 3 2 2 2 1 2 2 -33.3% 19 8 8 10 9 7 7 5 6 5 6 -25.0% 20 5 5 5 4 4+ 4+ 4+ 4+ 4+ 4+ -20.0% 21 6 5 6 5 5 5 5 5 5+ 5+ -16.7% 22 3 6 5 5 5+ 5+ 5+ 5+ 5+ 5+ +66.7% 23 0 0 0 0 0 0 0 0 0 0 24 0 0 0 0 0 0+ 0+ 0+ 0+ 0+ 25 0 0 0 0 0 0 0 0 0+ 0+
Table of Individual Patient Scores over Treatment Days (Average Pain in the Past 24 Hours) – Lower Extremities
11 5 5 7 5 6 5 2 2 4 2 -60.0% 12 6 6 5 5 5 4 4 4 4 3 -50.0% 13 5 5 5 5 5 5 3 3 4 3 -40.0%
20 5 5 5 4 4+ 4+ 4+ 4+ 4+ 4+ -20.0% 21 6 5 6 5 5 5 5 5 5+ 5+ -16.7% 22 3 6 5 5 5+ 5+ 5+ 5+ 5+ 5+ +66.7%
1 5 7 2 2 0 0 0 0 0 0 -100% 2 4 4 6 2 1 0 0+ 0+ 0+ 0+ -100% 3 9 8 7 0 0+ 0+ 0+ 0+ 0+ 0+ -100% 4 5 4 3 0 0 1 0 0 0 0 -100% 5 8 8 0 3 3 2 1 1 0 0 -100% 6 5 5 5 5 4 3 3 2 0 0 -100% 7 5 5 5 4 3 3 2 2 1 0 -100%
![Page 66: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/66.jpg)
Treatment Day 1 2 3 4 5 6 7 8 9 10
Study ID Change
(%) Upper Extremities
26 2 2 1 0 0 3 0 0 0 0 -100%
27 9 6 5 2 1 0 1 1+ 1+ 1+ -88.9%
28 8 1 0 1 1 1+ 1+ 1+ 1+ 1+ -87.5%
29 5 6 4 2 2+ 2+ 2+ 2+ 2+ 2+ -60.0%
30 8 6 6 5 5 5 5 5 4 4 -50.0%
31 9 6 5 6 5 7 5 5 5 5 -44.4%
32 3 3 3 3 3 2 3 2 2 2 -33.3%
33 9 10 7 7 6 6+ 6+ 6+ 6+ 6+ -33.3%
34 3 3 2 2+ 2+ 2+ 2+ 2+ 2+ 2+ -33.3%
35 6 6 3 5 4 4* 4* 4* 4* 4* -33.3%
36 9 9 8 8+ 8+ 8+ 8+ 8+ 8+ 8+ -11.1%
37 8 8+ 8+ 8+ 8+ 8+ 8+ 8+ 8+ 8+ 0.0%
Average Pain 5.7 5.2 4.5 3.8 3.4 3.5 3.0 2.8 2.8 2.6 -53.8%
(SD) 2.6 2.5 2.6 2.5 2.4 2.4 2.4 2.4 2.4 2.4 (7.4%)
Average Pain 5.7 5.2 4.5 3.8 3.4 3.5 3.0 2.8 2.8 2.6 -53.8%
26 2 2 1 0 0 3 0 0 0 0 -100%
27 9 6 5 2 1 0 1 1+ 1+ 1+ -88.9%
28 8 1 0 1 1 1+ 1+ 1+ 1+ 1+ -87.5%
Table of Individual Patient Scores over Treatment Days (Average Pain in the Past 24 Hours) – Upper Extremities
35 6 6 3 5 4 4* 4* 4* 4* 4* -33.3%
36 9 9 8 8+ 8+ 8+ 8+ 8+ 8+ 8+ -11.1%
37 8 8+ 8+ 8+ 8+ 8+ 8+ 8+ 8+ 8+ 0.0%
Pachman et al; Sup Care in Cancer, 2014
![Page 67: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/67.jpg)
![Page 68: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/68.jpg)
Starkweather et al. Res Nur Health 2015 38(1):29-38
• DB, randomized, controlled trial
• 30 pts with LBP
• Significant decreases in: • Worst BPI pain and interference scores
• Pain sensitivity
• mRNA expression of 17 pain genes
Fifteenth Trial/Report
![Page 69: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/69.jpg)
There is ‘no proof’ that Scrambler works
• All of the reports have weaknesses
• No large placebo-controlled trials-ideally should be 2
• Potential COI • Some reports (4) involve inventor
• Multiple prior claims of therapies that have
not been able to withstand the test of time/investigation
![Page 70: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/70.jpg)
Why do ‘I believe that it works’?
• Independent investigators have replicated findings reported by Marineo
• 2 positive randomized controlled trials
• Multiple positive reports (>700 patients) from multiple investigators
• All reports, save one small abstract, were considered to be positive, by the authors
• I’ve seen too many anecdotes to believe it doesn’t work
![Page 71: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/71.jpg)
Conclusions-ASCO Guidelines • Duloxetine does work a little bit and is the best
demonstrated treatment-I recommend/use • Gabapentin is commonly used for lots of neuropathies, but
data are lacking for CIPN-I do not use, many do • Tricyclic antidepressants are used for neuropathies but
limited data for CIPN- I do not use, some do
• Topical baclofen/amytriptyline/ketamine-The jury is still out
![Page 72: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/72.jpg)
There is no proof that Scrambler therapy provides remarkable benefit • Scientific hat
I believe that Scrambler therapy provides remarkable benefit • Clinical and scientific hats
Scrambler therapy should be clinically available at Mayo • Clinical hat
Conclusions-Scrambler
![Page 73: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/73.jpg)
![Page 74: Chemotherapy-Induced Neuropathy: Standard and Innovative ... · Standard and Innovative Treatment Approaches Charles Loprinzi MD Regis Professor of Breast Cancer Research cloprinzi@mayo.edu](https://reader030.vdocuments.site/reader030/viewer/2022040808/5e4c1c6d3699c37e3e0271cd/html5/thumbnails/74.jpg)
Thanks for your attention!!